Cargando…

Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer

BACKGROUND: Cancer immunotherapies are emerging as promising treatment strategies for ovarian cancer patients that experience disease relapse following first line therapy. As such, identifying strategies to bolster anti-tumor immunity and limit immune suppression, while recognizing diverse patterns...

Descripción completa

Detalles Bibliográficos
Autores principales:	McGray, A. J. Robert, Huang, Ruea-Yea, Battaglia, Sebastiano, Eppolito, Cheryl, Miliotto, Anthony, Stephenson, Kyle B., Lugade, Amit A., Webster, Gill, Lichty, Brian D., Seshadri, Mukund, Kozbor, Danuta, Odunsi, Kunle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637574/ https://www.ncbi.nlm.nih.gov/pubmed/31315674 http://dx.doi.org/10.1186/s40425-019-0641-x

Ejemplares similares

A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer
por: McGray, A. J. R., et al.
Publicado: (2021)

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
por: Huang, Ruea-Yea, et al.
Publicado: (2016)

Development and applications of oncolytic Maraba virus vaccines
por: Pol, Jonathan G, et al.
Publicado: (2018)

Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies
por: Odunsi, Adekunle, et al.
Publicado: (2020)

CXCR6 by increasing retention of memory CD8(+) T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer
por: Muthuswamy, Ravikumar, et al.
Publicado: (2021)

LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8(+) T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
por: Huang, Ruea-Yea, et al.
Publicado: (2015)

Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer
por: Want, Muzamil Yaqub, et al.
Publicado: (2019)

Characterizing Cellular Responses During Oncolytic Maraba Virus Infection
por: Hassanzadeh, Golnoush, et al.
Publicado: (2019)

Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation
por: Mistarz, Anna, et al.
Publicado: (2021)

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials
por: Pol, Jonathan G., et al.
Publicado: (2018)

Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats
por: Hummel, Jeff, et al.
Publicado: (2017)

Spatial and temporal epithelial ovarian cancer cell heterogeneity impacts Maraba virus oncolytic potential
por: Tong, Jessica G., et al.
Publicado: (2017)

Reprogramming the tumor microenvironment leverages CD8(+) T cell responses to a shared tumor/self antigen in ovarian cancer
por: Mistarz, Anna, et al.
Publicado: (2023)

Correction to: Tcf‑1 protects anti‑tumor TCR‑engineered CD8(+) T‑cells from GzmB mediated self‑destruction
por: Zangari, Brendan, et al.
Publicado: (2022)

Tcf-1 protects anti-tumor TCR-engineered CD8(+) T-cells from GzmB mediated self-destruction
por: Zangari, Brendan, et al.
Publicado: (2022)

IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation
por: Amobi-McCloud, Adaobi, et al.
Publicado: (2021)

Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy
por: Komorowski, Marcin P, et al.
Publicado: (2016)

Whole‐exome sequencing of ovarian cancer families uncovers putative predisposition genes
por: Zhu, Qianqian, et al.
Publicado: (2019)

Early and late neuropathological features of meningoencephalitis associated with Maraba virus infection
por: Maia-Farias, A., et al.
Publicado: (2020)

BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer control
por: McGray, A J Robert, et al.
Publicado: (2023)

Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning
por: Pol, Jonathan G, et al.
Publicado: (2020)

Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer
por: Tsuji, Takemasa, et al.
Publicado: (2020)

Elevated Expression of the Serine-Arginine Protein Kinase 1 Gene in Ovarian Cancer and Its Role in Cisplatin Cytotoxicity In Vitro
por: Odunsi, Kunle, et al.
Publicado: (2012)

Recruitment of Intratumoral CD103(+) Dendritic Cells by a CXCR4 Antagonist-Armed Virotherapy Enhances Antitumor Immunity
por: Mistarz, Anna, et al.
Publicado: (2019)

Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression
por: Nelson, Adam, et al.
Publicado: (2022)

Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice
por: Gil, M, et al.
Publicado: (2011)

WHSC1/NSD2 regulates immune infiltration in prostate cancer
por: Want, Muzamil Y, et al.
Publicado: (2021)

Prime-boost using Separate Oncolytic Viruses in Combination with Checkpoint Blockade Improves Anti-tumor Therapy
por: Ilett, Elizabeth, et al.
Publicado: (2016)

Split T Cell Tolerance against a Self/Tumor Antigen: Spontaneous CD4(+) but Not CD8(+) T Cell Responses against p53 in Cancer Patients and Healthy Donors
por: Tsuji, Takemasa, et al.
Publicado: (2011)

Oncolytic Viruses: Therapeutics With an Identity Crisis
por: Breitbach, Caroline J., et al.
Publicado: (2016)

Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer
por: Liu, Song, et al.
Publicado: (2019)

Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study
por: Eng, Kevin H., et al.
Publicado: (2018)

Whole-Genome Sequencing Identifies PPARGC1A as a Putative Modifier of Cancer Risk in BRCA1/2 Mutation Carriers
por: Zhu, Qianqian, et al.
Publicado: (2022)

A novel cancer/testis antigen KP-OVA-52 identified by SEREX in human ovarian cancer is regulated by DNA methylation
por: KIM, KANG-MI, et al.
Publicado: (2012)

Oncolytic Viruses: Priming Time for Cancer Immunotherapy
por: Russell, Luke, et al.
Publicado: (2019)

Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
por: Roy, D. G., et al.
Publicado: (2021)

Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
por: Oseledchyk, Anton, et al.
Publicado: (2018)

Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
por: Saha, Dipongkor, et al.
Publicado: (2017)

Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
por: Marchini, Antonio, et al.
Publicado: (2016)

TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy
por: Valenzuela-Cardenas, Miriam, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3usmo91s7jl2k5epilvjbermue